Search results
Results from the WOW.Com Content Network
RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...
D.H. Blair underwrote hundreds of companies, many in the biotechnology industry. Several D.H. Blair brokers were indicted for fraud, and the firm was shut down. Rosenwald headed a team of three physician-financiers who searched in the medical community for the latest developments that could be marketed with the help of private investment.
The Pennsylvania State Hospital System is a network of psychiatric hospitals operated by the Commonwealth of Pennsylvania. At its peak in the late 1940s the system operated more than twenty hospitals and served over 43,000 patients. As of 2011 fewer than nine sites remain in use, and many of those serve far fewer patients than they once did ...
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
Born: 1948 (age 76–77) Education: Miami University George Washington University (): Known for: Schizophrenia research NIMH CATIE study [1]: Children: 2: Awards: Lieber Prize for Schizophrenia Research from the National Association for Research in Schizophrenia and Affective Disorders
The scientific principles which Dr. Noyes incorporated into his work are carried over through the Arthur Noyes Forensic Center (Building #51), the Arthur P. Noyes Schizophrenia Conference [25] and the Arthur P. Noyes Research Foundation. [26] To this day Dr. Noyes' portrait remains hung in the administration building in the hospital as a homage ...
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT 2A and σ 2 receptor antagonist under development by Minerva Neurosciences for the treatment of schizophrenia.
In New York ARC v. Rockefeller, parents of 5,000 residents at the Willowbrook State School in Staten Island, New York, filed suit over the inhumane living conditions at that institution, where residents were abused and neglected. A 1972 television broadcast from the Willowbrook State School, titled "Willowbrook: The Last Great Disgrace ...